checkedThe Peter Attia Drive2026-11-16last verified 2026-11-16

does methylene blue block mao and risk serotonin toxicity with ssris? yes, even at standard doses

verdict: undersold
the real number is bigger, or worse, than claimed
“as you know, it can inhibit monomine oxidasis which detoxify dopamine and serotonin and people on serotonin”

a guest, a mitochondrial biologist (not a physician) said on The Peter Attia Drive, 2026-11-16, at 2:01:43. hear it in context →

first, the part that holds

the core of this is right. methylene blue inhibits monoamine oxidase, specifically MAO-A, and when it is combined with SSRIs and other serotonergic drugs it can cause serotonin toxicity, sometimes fatal. that is now a boxed warning on the FDA label.

what we found when we went and looked

the FDA label for methylene blue injection (NDA 204630, revised 01/2024) carries a boxed warning: it "may cause serious or fatal serotonergic syndrome" with serotonergic drugs. the label says literature reports suggest methylene blue "is a potent reversible inhibitor of monoamine oxidase." a 2007 enzyme study found methylene blue is a potent, tight-binding inhibitor of MAO-A. at concentrations reached after intravenous doses, it estimated MAO-A would be fully inhibited. where the claim falls short is "taking too much." the warning is attached to the standard labeled dose of 1 mg/kg, not to overdose. one 2018 report describes the syndrome after an oral urinary analgesic that contains methylene blue. the record points to more risk than "too much" implies, not less.

assertion by assertion

assertionverdictwhat the record says
methylene blue inhibits monoamine oxidaseconfirmeda 2007 study using purified human enzyme found methylene blue is a potent, tight-binding, reversible inhibitor of MAO-A. it inhibits MAO-B only at much higher concentrations. the FDA label (section 7) says literature reports suggest it is "a potent reversible inhibitor of monoamine oxidase." limitation: the abstract we read gives no IC50 values, and the label states the interaction mechanism "is not clearly understood." [1][2]
taking methylene blue alongside serotonergic medication such as SSRIs can cause serotonin toxicityconfirmedthe boxed warning names SSRIs, SNRIs, MAOIs and opioids and says to avoid using them together with methylene blue. section 5.1 says "some of the reported cases were fatal" and advises not taking serotonergic drugs within 72 hours after the last dose. a 2018 systematic review found 50 published cases, all in people on serotonergic antidepressants, with one death. a 2010 systematic review found 26 people with acute confusion after methylene blue infusion, and 24 of them were taking a serotonin reuptake inhibitor. [1][3][4]
the danger comes from taking too much methylene blueundersoldthe boxed warning applies at the labeled dose of 1 mg/kg IV, and it says to avoid the combination outright. if the combination cannot be avoided, the label says to use "the lowest possible dose" and watch for CNS effects for up to 4 hours. the 2007 study estimated MAO-A is fully inhibited at concentrations reported after IV dosing. the label's overdose section lists toxicity at 3 mg/kg or more, but those effects are cardiopulmonary and hemolytic, not serotonin toxicity. most published cases come from surgical IV use. one 2018 case report describes the syndrome after an oral urinary analgesic containing methylene blue. limitation: the dose of that oral product is not stated in the abstract, and no source we read sets a safe oral dose. [1][2][3]
monoamine oxidase breaks down ("detoxifies") dopamine and serotonin, and that is the route to toxicityunverifiablethe 2007 study ties serotonin toxicity to disrupted 5-hydroxytryptamine (serotonin) metabolism through MAO-A inhibition. it also estimates partial MAO-B inhibition at IV concentrations. none of the sources we read address dopamine in this interaction. "detoxify" is a loose word for metabolic breakdown. [2]
how often the interaction happensunverifiablea 2025 US database study found 249,131 people who received methylene blue around surgery. 25,282 of them (10.14%) were also on serotonergic drugs, mostly SSRIs (63.04 per 1,000). the abstract reports exposure, not how many developed serotonin syndrome, so we found no incidence rate. [5]

both directions

for the speaker: both mechanism and outcome are on the primary record. a purified-enzyme study shows potent, reversible MAO-A inhibition. the FDA added a boxed warning naming SSRIs, SNRIs, MAOIs and opioids and noting fatal cases. two systematic reviews (2010, 2018) collect dozens of cases, almost all in people on serotonergic antidepressants. the label's 72-hour washout advice and its instruction to monitor for CNS effects for 4 hours show the regulator treats this as a real, clinically relevant interaction.

against: the wording "taking too much" suggests the risk is about dose. the record does not support that limit. the warning sits on the standard 1 mg/kg IV dose, the enzyme study estimates full MAO-A inhibition at ordinary IV concentrations, and one case involved an oral, low-strength urinary product. the speaker also brings in dopamine. the sources we read tie the interaction to serotonin through MAO-A, and say MAO-B is inhibited only at much higher concentrations.

what this cannot say

nearly all published cases involve intravenous methylene blue given around surgery or for shock. the evidence for oral use is one case report, and the abstract does not give the dose. we found no data on the over-the-counter or "nootropic" oral doses people now take, so we cannot say at what oral dose risk begins or whether there is a safe threshold. case reports and reviews of case reports cannot give an incidence rate. the large 2025 database study measured co-exposure, not outcomes. we read abstracts and the label, not full texts. the full 2007 paper may contain potency numbers we did not see. we could not load the 2011 FDA safety communication itself (the fda.gov URLs returned 404), so we rely on the current label.

sources, each one fetched and read

  1. US FDA, prescribing information for methylene blue injection, NDA 204630, revised 01/2024 What we read there: boxed warning: "may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use... with (SSRIs), (SNRIs), (MAOIs) and opioids." section 7: literature reports suggest it "is a potent reversible inhibitor of monoamine oxidase." section 5.1: "Some of the reported cases were fatal" and advises no serotonergic drugs within 72 hours after the last dose. labeled dose is 1 mg/kg IV. Fetched 2026-11-16 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204630s021lbl.pdf
  2. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology 2007;152(6):946-51. PMID 17721552, doi:10.1038/sj.bjp.0707430 What we read there: methylene blue is a potent, tight-binding, reversible MAO-A inhibitor that inhibits MAO-B only at much higher concentrations. at concentrations reported after IV administration, MAO-A would be fully inhibited and MAO-B partially inhibited, enough to perturb serotonin metabolism and explain serotonin toxicity in patients on SSRIs. Fetched 2026-11-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/17721552/
  3. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics 2018. PMID 30104021 What we read there: "23 manuscripts were identified, resulting in 50 unique cases of MB-induced SS"; "Concurrent treatment with serotonergic antidepressants was described in all 50 cases"; one fatality; all prior cases were parenteral, and "our case suggests that SS can be induced by oral administration of MB-containing agents." Fetched 2026-11-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/30104021/
  4. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics 2010. PMID 20484716 (read within this multi-record PubMed fetch) What we read there: nine case reports and two retrospective reviews: "26 patients developed an acute confusional state after MB infusion; 24 of these patients were taking an SRI"; serotonin syndrome was judged a possible diagnosis in all 25 of the patients on a serotonergic drug. Fetched 2026-11-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/32951524/
  5. Prevalence of serotonergic drug use in patients exposed to perioperative methylene blue: a cross-sectional study. Cureus 2025;17(3):e81090. PMID 40271333 What we read there: 249,131 patients received perioperative methylene blue; 25,282 (10.14%) were concomitantly on serotonergic drugs, with SSRIs at 63.04 per 1,000; no serotonin syndrome incidence is reported in the abstract. Fetched 2026-11-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/40271333/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam